Do analysts rate IXHL or ORMP?

Incannex Healthcare presently has a consensus target price of $18.00, suggesting a potential upside of 443.81%. Given Incannex Healthcare's higher possible upside, analysts plainly believe Incannex Healthcare is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Incannex Healthcare 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is IXHL or ORMP more profitable?

Oramed Pharmaceuticals' return on equity of -5.37% beat Incannex Healthcare's return on equity. Company Net Margins Return on Equity Return on Assets Incannex Healthcare N/A -81.01% -76.11% Oramed Pharmaceuticals N/A -5.37% -4.83%

Is IXHL or OKUR more profitable?

OnKure Therapeutics' return on equity of -61.02% beat Incannex Healthcare's return on equity. Company Net Margins Return on Equity Return on Assets Incannex Healthcare N/A -81.01% -76.11% OnKure Therapeutics N/A -61.02% -55.99%

Incannex Healthcare (IXHL) Competitors

$3.31 -0.08 (-2.36%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$3.28 -0.03 (-0.88%)

As of 07:32 AM Eastern

Compare

IXHL vs. ORMP, IMDX, PLX, OKUR, and LENZ

Should you buy Incannex Healthcare stock or one of its competitors? MarketBeat compares Incannex Healthcare with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Incannex Healthcare include Oramed Pharmaceuticals (ORMP), Oncocyte (IMDX), Protalix BioTherapeutics (PLX), OnKure Therapeutics (OKUR), and LENZ Therapeutics (LENZ). These companies are all part of the "pharmaceutical products" industry.

How does Incannex Healthcare compare to Oramed Pharmaceuticals?

Incannex Healthcare (NASDAQ:IXHL) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

Oramed Pharmaceuticals has higher revenue and earnings than Incannex Healthcare. Incannex Healthcare is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	$90K	440.23	-$46.88M	-$1.55	N/A
Oramed Pharmaceuticals	$2M	80.84	$64.05M	$2.59	1.53

Oramed Pharmaceuticals' return on equity of -5.37% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-81.01%	-76.11%
Oramed Pharmaceuticals	N/A	-5.37%	-4.83%

0.4% of Incannex Healthcare shares are owned by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. 1.3% of Incannex Healthcare shares are owned by insiders. Comparatively, 17.8% of Oramed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Incannex Healthcare and Incannex Healthcare both had 1 articles in the media. Incannex Healthcare's average media sentiment score of 1.89 beat Oramed Pharmaceuticals' score of 1.87 indicating that Incannex Healthcare is being referred to more favorably in the media.

Company	Overall Sentiment
Incannex Healthcare	Very Positive
Oramed Pharmaceuticals	Very Positive

Incannex Healthcare has a beta of 6.95, meaning that its share price is 595% more volatile than the broader market. Comparatively, Oramed Pharmaceuticals has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market.

Incannex Healthcare presently has a consensus target price of $18.00, suggesting a potential upside of 443.81%. Given Incannex Healthcare's higher possible upside, analysts plainly believe Incannex Healthcare is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Oramed Pharmaceuticals beats Incannex Healthcare on 8 of the 13 factors compared between the two stocks.

How does Incannex Healthcare compare to Oncocyte?

Incannex Healthcare (NASDAQ:IXHL) and Oncocyte (NASDAQ:IMDX) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

In the previous week, Incannex Healthcare and Incannex Healthcare both had 1 articles in the media. Incannex Healthcare's average media sentiment score of 1.89 beat Oncocyte's score of 1.87 indicating that Incannex Healthcare is being referred to more favorably in the media.

Company	Overall Sentiment
Incannex Healthcare	Very Positive
Oncocyte	Very Positive

0.4% of Incannex Healthcare shares are owned by institutional investors. Comparatively, 55.4% of Oncocyte shares are owned by institutional investors. 1.3% of Incannex Healthcare shares are owned by insiders. Comparatively, 2.2% of Oncocyte shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Incannex Healthcare has higher earnings, but lower revenue than Oncocyte. Oncocyte is trading at a lower price-to-earnings ratio than Incannex Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	$90K	440.23	-$46.88M	-$1.55	N/A
Oncocyte	$4.05M	36.60	-$50.22M	-$1.48	N/A

Incannex Healthcare has a beta of 6.95, indicating that its stock price is 595% more volatile than the broader market. Comparatively, Oncocyte has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market.

Incannex Healthcare currently has a consensus target price of $18.00, indicating a potential upside of 443.81%. Oncocyte has a consensus target price of $12.00, indicating a potential upside of 161.44%. Given Incannex Healthcare's higher probable upside, analysts clearly believe Incannex Healthcare is more favorable than Oncocyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Incannex Healthcare has a net margin of 0.00% compared to Oncocyte's net margin of -2,454.64%. Oncocyte's return on equity of 0.00% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-81.01%	-76.11%
Oncocyte	-2,454.64%	N/A	-96.96%

Summary

Incannex Healthcare beats Oncocyte on 8 of the 13 factors compared between the two stocks.

How does Incannex Healthcare compare to Protalix BioTherapeutics?

Incannex Healthcare (NASDAQ:IXHL) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

Incannex Healthcare presently has a consensus price target of $18.00, suggesting a potential upside of 443.81%. Protalix BioTherapeutics has a consensus price target of $12.00, suggesting a potential upside of 402.09%. Given Incannex Healthcare's higher probable upside, equities analysts clearly believe Incannex Healthcare is more favorable than Protalix BioTherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Incannex Healthcare had 1 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 1 mentions for Incannex Healthcare and 0 mentions for Protalix BioTherapeutics. Incannex Healthcare's average media sentiment score of 1.89 beat Protalix BioTherapeutics' score of 0.00 indicating that Incannex Healthcare is being referred to more favorably in the media.

Company	Overall Sentiment
Incannex Healthcare	Very Positive
Protalix BioTherapeutics	Neutral

Protalix BioTherapeutics has higher revenue and earnings than Incannex Healthcare. Incannex Healthcare is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	$90K	440.23	-$46.88M	-$1.55	N/A
Protalix BioTherapeutics	$76.38M	2.52	$8.31M	$0.18	13.28

Incannex Healthcare has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-81.01%	-76.11%
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

0.4% of Incannex Healthcare shares are owned by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 1.3% of Incannex Healthcare shares are owned by company insiders. Comparatively, 6.7% of Protalix BioTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Protalix BioTherapeutics beats Incannex Healthcare on 8 of the 14 factors compared between the two stocks.

How does Incannex Healthcare compare to OnKure Therapeutics?

Incannex Healthcare (NASDAQ:IXHL) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership.

In the previous week, OnKure Therapeutics had 2 more articles in the media than Incannex Healthcare. MarketBeat recorded 3 mentions for OnKure Therapeutics and 1 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 1.89 beat OnKure Therapeutics' score of 0.29 indicating that Incannex Healthcare is being referred to more favorably in the media.

Company	Overall Sentiment
Incannex Healthcare	Very Positive
OnKure Therapeutics	Neutral

0.4% of Incannex Healthcare shares are held by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are held by institutional investors. 1.3% of Incannex Healthcare shares are held by insiders. Comparatively, 17.9% of OnKure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Incannex Healthcare has higher revenue and earnings than OnKure Therapeutics. Incannex Healthcare is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	$90K	440.23	-$46.88M	-$1.55	N/A
OnKure Therapeutics	N/A	N/A	-$59.52M	-$4.33	N/A

Incannex Healthcare has a beta of 6.95, suggesting that its share price is 595% more volatile than the broader market. Comparatively, OnKure Therapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market.

Incannex Healthcare currently has a consensus target price of $18.00, suggesting a potential upside of 443.81%. OnKure Therapeutics has a consensus target price of $27.00, suggesting a potential upside of 556.93%. Given OnKure Therapeutics' higher possible upside, analysts plainly believe OnKure Therapeutics is more favorable than Incannex Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
OnKure Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

OnKure Therapeutics' return on equity of -61.02% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-81.01%	-76.11%
OnKure Therapeutics	N/A	-61.02%	-55.99%

Summary

OnKure Therapeutics beats Incannex Healthcare on 7 of the 12 factors compared between the two stocks.

How does Incannex Healthcare compare to LENZ Therapeutics?

LENZ Therapeutics (NASDAQ:LENZ) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

54.3% of LENZ Therapeutics shares are owned by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are owned by institutional investors. 8.3% of LENZ Therapeutics shares are owned by company insiders. Comparatively, 1.3% of Incannex Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

LENZ Therapeutics currently has a consensus price target of $29.80, indicating a potential upside of 469.79%. Incannex Healthcare has a consensus price target of $18.00, indicating a potential upside of 443.81%. Given LENZ Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe LENZ Therapeutics is more favorable than Incannex Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Incannex Healthcare has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -519.30%. LENZ Therapeutics' return on equity of -46.82% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	-519.30%	-46.82%	-43.32%
Incannex Healthcare	N/A	-81.01%	-76.11%

In the previous week, LENZ Therapeutics had 6 more articles in the media than Incannex Healthcare. MarketBeat recorded 7 mentions for LENZ Therapeutics and 1 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 1.89 beat LENZ Therapeutics' score of 0.57 indicating that Incannex Healthcare is being referred to more favorably in the news media.

Company	Overall Sentiment
LENZ Therapeutics	Positive
Incannex Healthcare	Very Positive

LENZ Therapeutics has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, Incannex Healthcare has a beta of 6.95, meaning that its stock price is 595% more volatile than the broader market.

Incannex Healthcare has lower revenue, but higher earnings than LENZ Therapeutics. Incannex Healthcare is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENZ Therapeutics	$19.09M	8.59	-$82.13M	-$3.60	N/A
Incannex Healthcare	$90K	440.23	-$46.88M	-$1.55	N/A

Summary

LENZ Therapeutics beats Incannex Healthcare on 10 of the 16 factors compared between the two stocks.

Get Incannex Healthcare News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IXHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IXHL vs. The Competition

Export

Metric	Incannex Healthcare	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$40.56M	$3.05B	$7.05B	$12.61B
Dividend Yield	N/A	2.06%	2.68%	8.00%
P/E Ratio	-2.14	19.17	27.11	24.26
Price / Sales	440.23	838.79	589.96	117.88
Price / Cash	N/A	56.80	29.22	49.36
Price / Book	1.60	4.22	10.74	6.29
Net Income	-$46.88M	$64.26M	$3.58B	$330.66M
7 Day Performance	-10.78%	-3.58%	-2.11%	-1.35%
1 Month Performance	-13.58%	2.12%	3.27%	-0.64%
1 Year Performance	-53.25%	20.35%	26.31%	19.08%

Incannex Healthcare Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IXHL Incannex Healthcare	3.4609 of 5 stars	$3.31 -2.4%	$18.00 +443.8%	-49.9%	$40.56M	$90K	N/A	3	Positive News
ORMP Oramed Pharmaceuticals	2.405 of 5 stars	$4.57 -0.7%	N/A	+85.4%	$188.26M	$2M	1.76	10	Positive News
IMDX Oncocyte	3.2982 of 5 stars	$5.64 -1.7%	$12.00 +112.8%	N/A	$185.35M	$4.05M	N/A	120
PLX Protalix BioTherapeutics	2.4845 of 5 stars	$2.30 -0.9%	$12.00 +421.7%	+69.5%	$185.32M	$76.38M	N/A	200
OKUR OnKure Therapeutics	2.7423 of 5 stars	$4.60 +0.4%	$27.00 +487.0%	+64.4%	$185.01M	N/A	N/A	N/A	News Coverage Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IXHL) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Incannex Healthcare (IXHL) Competitors

IXHL vs. ORMP, IMDX, PLX, OKUR, and LENZ

How does Incannex Healthcare compare to Oramed Pharmaceuticals?

Summary

How does Incannex Healthcare compare to Oncocyte?

Summary

How does Incannex Healthcare compare to Protalix BioTherapeutics?

Summary

How does Incannex Healthcare compare to OnKure Therapeutics?

Summary

How does Incannex Healthcare compare to LENZ Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IXHL vs. The Competition

Incannex Healthcare Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Incannex Healthcare (IXHL) Competitors

IXHL vs. ORMP, IMDX, PLX, OKUR, and LENZ

How does Incannex Healthcare compare to Oramed Pharmaceuticals?

Which has better earnings & valuation, IXHL or ORMP?

Is IXHL or ORMP more profitable?

Do insiders and institutionals have more ownership in IXHL or ORMP?

Does the media prefer IXHL or ORMP?

Which has more risk and volatility, IXHL or ORMP?

Do analysts rate IXHL or ORMP?

Summary

How does Incannex Healthcare compare to Oncocyte?

Does the media refer more to IXHL or IMDX?

Do institutionals and insiders have more ownership in IXHL or IMDX?

Which has preferable earnings & valuation, IXHL or IMDX?

Which has more volatility and risk, IXHL or IMDX?

Do analysts prefer IXHL or IMDX?

Is IXHL or IMDX more profitable?

Summary

How does Incannex Healthcare compare to Protalix BioTherapeutics?

Do analysts rate IXHL or PLX?

Does the media refer more to IXHL or PLX?

Which has stronger earnings & valuation, IXHL or PLX?

Is IXHL or PLX more profitable?

Do institutionals and insiders hold more shares of IXHL or PLX?

Summary

How does Incannex Healthcare compare to OnKure Therapeutics?

Does the media refer more to IXHL or OKUR?

Do insiders and institutionals hold more shares of IXHL or OKUR?

Which has higher earnings & valuation, IXHL or OKUR?

Which has more risk and volatility, IXHL or OKUR?

Do analysts recommend IXHL or OKUR?

Is IXHL or OKUR more profitable?

Summary

How does Incannex Healthcare compare to LENZ Therapeutics?

Do insiders and institutionals have more ownership in LENZ or IXHL?

Do analysts prefer LENZ or IXHL?

Is LENZ or IXHL more profitable?

Does the media prefer LENZ or IXHL?

Which has more volatility & risk, LENZ or IXHL?

Which has stronger valuation & earnings, LENZ or IXHL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IXHL vs. The Competition

Incannex Healthcare Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools